Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

0.9415
-0.0020-0.21%
Post-market: 0.94480.0033+0.35%19:49 EDT
Volume:1.42M
Turnover:1.33M
Market Cap:107.89M
PE:-0.57
High:0.9695
Open:0.9695
Low:0.9102
Close:0.9435
Loading ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

Simply Wall St.
·
08 Mar

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties

TIPRANKS
·
07 Mar

Wedbush Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
07 Mar

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties

TIPRANKS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)

TIPRANKS
·
07 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE) and Stevanato Group (STVN)

TIPRANKS
·
06 Mar

Fate Therapeutics Price Target Maintained With a $5.00/Share by Wedbush

Dow Jones
·
06 Mar

Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
06 Mar

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Zacks
·
06 Mar

Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)

TIPRANKS
·
06 Mar

Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position

TIPRANKS
·
06 Mar

Fate Therapeutics price target lowered to $3 from $5 at Stifel

TIPRANKS
·
06 Mar

Barclays Keeps Their Buy Rating on Fate Therapeutics (FATE)

TIPRANKS
·
06 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fate Therapeutics (FATE), Organon (OGN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
06 Mar

Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties

TIPRANKS
·
06 Mar

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
06 Mar